Following a full submission
sitagliptin (Januvia®) is accepted for restricted use within NHS Scotland for treatment of patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin when diet and exercise, plus metformin, do not provide adequate glycaemic control. It should be restricted to use in patients only when the addition of sulphonylureas is not appropriate, and represents an alternative to other agents such as thiazolidinediones.
Efficacy, as assessed by measurement of HbA1c, is similar to sulphonylurea and thiazolidinedione drugs added at this stage in therapy. It appears to have minimal effects on body weight.
|Drug Name:||sitagliptin (Januvia)|
|SMC Drug ID:||408/07|
|Indication:||Type 2 diabetes|
|Sub Category:||6.1 Drugs used in diabetes|
|Submission Type:||Full submission|
|Date Advice Published:||8 October 2007|